Justin B. Klee - Jan 6, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Jan 6, 2023
Transactions value $
$216,629
Form type
4
Date filed
1/10/2023, 06:12 PM
Previous filing
May 6, 2022
Next filing
Mar 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale $149K +4.12K +0.14% $36.08 2.89M Jan 6, 2023 Direct F1, F2
transaction AMLX Common Stock Sale $67.9K +1.85K +0.06% $36.79 2.89M Jan 6, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.